380 likes | 468 Views
3RD SEMINAR. INNATE IMMUNITY : ANTIVIRAL STATE, KILLER CELLS, THE COMPLEMENT SYSTEM. DANGER SIGNALS ARE TRANSLATED TO CYTOKINE SECRETION THROUGH VARIOUS MOLECULAR SENSORS IN DC SUBTYPES. 4. 6. 6. 2. 1. 1. NLR. RLR. RLR. IL-1 β IL-12/23 IL-10. IFN α IFN β. 5. 10. 7. 3. 9. 7.
E N D
3RD SEMINAR INNATE IMMUNITY:ANTIVIRAL STATE,KILLER CELLS, THE COMPLEMENT SYSTEM
DANGER SIGNALS ARE TRANSLATED TO CYTOKINE SECRETION THROUGH VARIOUS MOLECULAR SENSORS IN DC SUBTYPES 4 6 6 2 1 1 NLR RLR RLR IL-1β IL-12/23 IL-10 IFNαIFNβ 5 10 7 3 9 7 8 Plasmacytoid DC Conventional DC TLR1 – bacteriallipoprotein (togetherwith TLR2) TLR2 –bacteriallipoprotein, peptidoglycane, lipoteicholicacid (heteromerwith TLR1 and TLR6) TLR3 –viraldsRNA TLR4 – bacterial LPS TLR5 – bacterialflagellin TLR6 –bacteriallipoprotein(togetherwithTLR2) TLR7 – viralssRNA TLR8 – viralssRNA TLR9 – unmethylatedCpG DNA TLR10 – modifiedviralnucleotides NLRs – microbialproducts, DAMPs RLRs – viraldsRNA
THE TYPE I INTERFERON RESPONSE: ANTIVIRAL STATE Plasmacytoid dendritic cells (pDCs) produce 1000x more type I interferon than other cells (Natural Interferon Producing Cells – NIPC) After viral infection they are accumulated at the T cell zone of the lymph nodes plasmacytoid dendritic cells
VIRUS-INDUCED TYPE I INTERFERON PRODUCTION Type I IFN receptor IFN response Virus IFN- IRF-3 NFB AP-1 IRF-3 IFN- paracrine IFN- IRF-7 autocrine Infected cell IFN response IFN- subtypes IRF: interferon regulatory factor
INTERFERON EFFECTOR PATHWAYSinduction of the „antiviral state” • 1.MxGTPase pathway • block viral transcription • 2. 2',5'-oligoadenylate-synthetase (OAS)-directed Ribonuclease L pathway • degrade viral RNA • 3. Protein kinase R (PKR) pathway (Ser/Thr kinase, dsRNA-dependent) • inhibit translation • 4. ISG15 ubiquitin-like pathway • modify protein function CONTROL ALL STEPS OF VIRAL REPLICATION
MULTIPLE EFFECTS OF TYPE I INTERFERONS Increasedcitotoxicity and proliferationof NK-cells TLR4 TRAM TRIF TLR7 TLR8 TLR9 TLR3 TRIF MyD88 TANK IRAK-1 Activation of - and γδT-cells TRAF-6 RIG-1 IKKε TBK1 IRF-7 Increasedantigenpresentation inmyeloiddendriticcells IRF-3 IRF-5 IFN-β, IFN-α IRF-7 Stimulation of Ig-production inB-cells Type I interferon receptor
EFFECTOR MECHANISMS OF INNATE IMMUNITY KILLER CELLS COMPLEMENT SYSTEM PHAGOCYTIC CELLS
NK CELLS • Similarfunctionstocytotoxic T cellsbut: • larger than lymphocytes • no rearranged antigen-specific receptors • contain large cytoplasmic granules • respond fast, circulate in a partly activated state
RECOGNITION AND KILLING BY NK CELLS KIR KAR KIR KAR • Contents of lytic granules: • Perforin: forming pores in the target cell membrane lysis • Granzyme: inducing apoptosis in the target cell
NK-CELLS PRR Virus-infected cell RECOGNITION ACTIVATION Lysis of infected cell IFN IL-12 RECOGNITION OF ALTERED HOST CELLS NK-cells Relative level/activity Kinetics of the activity of the complement system and NK cells in virus infection Complement system days NATURAL KILLER CELL ACTIVATION
EFFECTOR MECHANISMS OF INNATE IMMUNITY KILLER CELLS COMPLEMENT SYSTEM PHAGOCYTIC CELLS
THE COMPLEMENT SYSTEM • The complement system is a set of plasma proteins that act in a cascade to attack and kill extracellular pathogens. • Approximately 30 components: • activating molecules • regulator factors • complement receptors • membrane proteins which inhibit the lysis of host cells • Most of the complement proteins and glycoproteins are produced in the liver in an inactive form (zymogen). Activation is induced by proteolytic cleavage.
AMPLIFICATION OF THE COMPLEMENT CASCADE limited proteolysis inactive precursors enzyme activating surface Activating surface needed!
THE C1 COMPLEX Collagen „legs” Gobular „heads” C1 is alwayspresentinserumbutitrequires an activatingsurfaceforactivation LowaffinitybindingtotheFcregion of antibody conformationalchange activation
THE CLASSICAL PATHWAY: FIXATION OF COMPLEMENT, GENERATION OF C3b BY THE CLASSICAL C3 CONVERTASE
Eukariotic cells GLYCOSYLATION OF PROTEINS IS DIFFERENT IN VARIOUS SPECIES Prokariotic cells galactose glucoseamine neuraminicacid (sialicacid) mannose (polymer = mannan)
MANNOSE-BINDING LECTIN (MBL) PATHWAY MBL: part of the collectin family • similar structure to C1 complex, MASP-1,2 ~ C1r,s • binds mannose and similar sugar molecules on the surface of bacteria, fungi, protozoa and viruses conformational change cleavage of C2 and C4 molecules MASP = MBL-associatedserin protease
C3b can derive from classical or the lectin pathway too Alternative pathway is instantly inactivated on eukaryotic cell surfaces (in the presence of sialic acid molecules)
THE CENTRAL COMPONENT OF THE COMPLEMENT SYSTEM Strong covalentbindingComplementfixation (3900000000000000 molecules/ml)
C5-CONVERTASE C3 convertase + C3b = C5 convertase (C4bC2bC3b) The classical and alternative C3convertase is different in structure but common in function
MEMBRANE ATTACK COMPLEX (MAC = C5b-C9n) MACsinthecellmembrane
COMPLEMENT ACTIVATION SUMMARY
COMPLEMENT SYSTEM CLASSICAL PATHWAY MB-LECTIN PATHWAY ALTERNATIVE PATHWAY Antigen-antibody complex Mannose Pathogen surface MBL MASP-1/MASP-2 Serin protease C4, C2 C3 B, D C1q, C1r, C1s Serin protease C4, C2 C4a* C3a, C5a C3 CONVERTASE Terminal C5b – C9 C3b Inflammatory peptide mediators Phagocyte recruitment Opsonization Binding to phagocyte CR Immune complex removal MAC Pathogen/cell lysis
HEREDITARY ANGIONEUROTIC EDEMA (HANE)(HEREDITARY C1INH DEFECT) Inhibition by C1INH in many steps • bradykinin and C2-kinin: enhance the permeability of postcapillarvenules edema • C1 is always active without activating surface because plasmin is always active Main symptoms: • swellings of skin, guts, respiratory tracts • serious acute abdominal pain, vomiting • larynx swelling – suffocation, may cause death Treatment: • iv C1INH, FFP, steroid • kallikrein and bradykinin receptor antagonists Children with symptoms of HANE
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) • Acquired clonal mutation of PIG-A gene in myeloid progenitors – no GPI-enchored proteins in the cell membrane of affected cells (rbc, plt, wbc) • CD59 and CD55 complement regulatory proteins are GPI-enchored proteins • No CD59 and/or CD55 PNH patients are highly susceptible to complement-mediated lysis • The lysis of red blood cells leads to high levels of hemoglobins in the blood that appears in the urine (hemoglobinuria) • Elevated levels of TF derived from complement-damaged leukocytes cause thromboses
Change in the colour of urine samples taken from PNH patient during the day
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) SYMPTOMS THERAPY Specific th.: eculizumab (Soliris) = anti-C5 monoclonalantibody Curative th.: bonemarrowtransplantation Alternative th.: steroids (generalimmunosuppression) Anticoagulants: s.c. heparin p.o. kumarin Ironreplacement Transfusion (filtered-irradiatedblood) • Haemolyticanaemia and associatedsymptoms • Haemoglobin and itsproductsintheurine • Thrombosis: • brainveins, • mesenthericveins, • hepaticveins (Budd-Chiari-syndrome) • May transformtoleukemiaorotherbonemarrowdiseases